Dutch National ITB Study in Children With Cerebral Palsy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-01-31

Study Completion Date

2007-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to determine the efficacy and safety of treatment with intrathecal baclofen for severe spasticity in children with cerebral palsy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Spasticity in cerebral palsy (CP) is a serious problem leading to pain, sleep disturbance, increased expenditure of energy and/or interference with positioning, transfers, dressing and body hygiene. In later stages, secondary phenomena, such as contractures, decubitus and heterotopic calcifications of joints or tendons may create large treatment problems. A substantial group of children with severe CP does not respond to regular treatments, such as physical therapy, orthopaedic surgery or oral medication. An effective treatment option for intractable spasticity is the continuous delivery of intrathecal baclofen (CITB). In 2000, the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) published a systematic review on the body of evidence about intrathecal baclofen (ITB) for spasticity in individuals with CP. It appeared that only a small and uncertain number of children had been studied. Except for two case-reports, none of the studies solely concerned children. The research methodology employed in three quarters of the available studies was not capable of confirming treatment effect. The AACPDM underlined the need for further high-level research in the form of prospective, randomized trials that use valid and reliable outcome measures in well described and homogeneous groups.

In 1998 the Dutch Study Group on Child Spasticity designed the Dutch national study on the effectiveness and safety of ITB for refractory spasticity in children with cerebral palsy. The Dutch national ITB study included four phases: 1\] the selection phase, 2\] the double-blind, placebo-controlled dose-escalation test treatment phase, 3\] the prospective, randomized, open-label implantation phase and 4\] the follow-up phase.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Palsy Spasticity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Cerebral palsy Spasticity Child Baclofen Intrathecal injection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

baclofen, intrathecal

Intervention Type DRUG

infusion pump for intrathecal baclofen, Synchromed, Medtronic

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age between 4 and 16 years
* spastic diplegia or tetraplegia as part of CP
* insufficient response to oral spasticity-reducing medication
* in a mixed CP syndrome, spasticity has to be the most prominent sign
* spasticity results in a decrease in the quality of life of the child and/or its caregivers
* sufficient motivation for participation in the study including availability for follow-up
* magnetic resonance imaging of the brain rules out progressive causes of spasticity

Exclusion Criteria

* hypersensitivity to baclofen
* contraindications for general anaesthesia
* insufficient general health
* intractable epileptic seizures
* infection of the lumbar skin
* a systemic infection

Minimum Eligible Age

4 Years

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Johan SH Vles, MD, PhD, Prof

Role: STUDY_CHAIR

Maastricht University Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Maastricht

Maastricht, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Butler C, Campbell S. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. AACPDM Treatment Outcomes Committee Review Panel. Dev Med Child Neurol. 2000 Sep;42(9):634-45. doi: 10.1017/s0012162200001183. No abstract available.

Reference Type BACKGROUND

PMID: 11034458 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PF-147

Identifier Type: -

Identifier Source: org_study_id